DiaSorin to acquire U.S.-based Luminex for around $1.8 billion

3
1
Favorite

DiaSorin to acquire U.S.-based Luminex for around $1.8 billion

Dow Jones2021-04-12

Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. $(LMNX)$ for around $1.8 billion.

DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal.

The deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the "attractive and high growth syndromic multiplex panel testing market," said a team of Jefferies analysts led by Peter Welford, in a note to clients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

tls
·2021-04-12
Yes
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2126105747?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-12 15:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2126105747","market":"us","top_or_hot":-1,"title":"DiaSorin to acquire U.S.-based Luminex for around $1.8 billion","media":"Dow Jones","content":"<p>Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. <a href=\"https://laohu8.com/S/LMNX\">$(LMNX)$</a> for around $1.8 billion. </p>\n<p>DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal. </p>\n<p>The deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the \"attractive and high growth syndromic multiplex panel testing market,\" said a team of Jefferies analysts led by Peter Welford, in a note to clients.</p>\n<p><img src=\"https://static.tigerbbs.com/99f914b9982794aefaa6b77dc56e799f\" tg-width=\"663\" tg-height=\"564\"></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiaSorin to acquire U.S.-based Luminex for around $1.8 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiaSorin to acquire U.S.-based Luminex for around $1.8 billion\n</h2>\n\n<h4 class=\"meta\">\n\n2021-04-12 15:47 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. $(LMNX)$ for around $1.8 billion. \nDiaSorin will pay $37 ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LMNX","symbol_name":"路明克斯","start_time":0,"source_url":null,"article_id":"2126105747","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2126105747","pubTimestamp":1618213620,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LMNX":"路明克斯"},"translate_title":"DiaSorin以约18亿美元收购美国Luminex","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LMNX":0.9},"content_text":"Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. $(LMNX)$ for around $1.8 billion. \nDiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal. \nThe deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the \"attractive and high growth syndromic multiplex panel testing market,\" said a team of Jefferies analysts led by Peter Welford, in a note to clients.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":342647626,"gmtCreate":1618215441565,"gmtModify":1704707605869,"author":{"id":"3561724332268799","authorId":"3561724332268799","name":"tls","avatar":"https://static.tigerbbs.com/c189b5977503c8e03b3c591e53e2ab48","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3561724332268799","authorIdStr":"3561724332268799"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/342647626","repostId":2126105747,"repostType":4,"repost":{"id":"2126105747","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1618213620,"share":"https://ttm.financial/m/news/2126105747?lang=&edition=fundamental","pubTime":"2021-04-12 15:47","market":"hk","language":"en","title":"DiaSorin to acquire U.S.-based Luminex for around $1.8 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2126105747","media":"Dow Jones","summary":"Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy ","content":"<p>Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. <a href=\"https://laohu8.com/S/LMNX\">$(LMNX)$</a> for around $1.8 billion. </p>\n<p>DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal. </p>\n<p>The deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the \"attractive and high growth syndromic multiplex panel testing market,\" said a team of Jefferies analysts led by Peter Welford, in a note to clients.</p>\n<p><img src=\"https://static.tigerbbs.com/99f914b9982794aefaa6b77dc56e799f\" tg-width=\"663\" tg-height=\"564\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DiaSorin to acquire U.S.-based Luminex for around $1.8 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDiaSorin to acquire U.S.-based Luminex for around $1.8 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-04-12 15:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. <a href=\"https://laohu8.com/S/LMNX\">$(LMNX)$</a> for around $1.8 billion. </p>\n<p>DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal. </p>\n<p>The deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the \"attractive and high growth syndromic multiplex panel testing market,\" said a team of Jefferies analysts led by Peter Welford, in a note to clients.</p>\n<p><img src=\"https://static.tigerbbs.com/99f914b9982794aefaa6b77dc56e799f\" tg-width=\"663\" tg-height=\"564\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LMNX":"路明克斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126105747","content_text":"Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. $(LMNX)$ for around $1.8 billion. \nDiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday. The price represents a 24% premium to Luminex's close on Feb. 24, the date prior to press speculation about a potential deal. \nThe deal is expected to close in the third quarter of 2021, pending regulatory approvals. Acquiring Luminex will boost DiaSorin's presence in molecular diagnostics, particularly in the \"attractive and high growth syndromic multiplex panel testing market,\" said a team of Jefferies analysts led by Peter Welford, in a note to clients.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}